Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
The American Journal of Medicine|May 29, 2018
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery DiseaseRenato D Lopes, Jan Steffel, Manuela Di Fusco, et al.
The American Journal of Medicine|August 11, 2020
Corrigendum to "Effectiveness and Safety of Oral Anticoagulants in Adults with Non-valvular Atrial Fibrillation Patients and Concomitant Coronary/Peripheral Artery Disease" American Journal of Medicine 131:09 (2018): 1074-1085.e4Renato D Lopes, Jan Steffel, Manuela Di Fusco, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2014
Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis modelJamese J Hilliard, Vivekananda Datta, Christine Tkaczyk, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Science Translational Medicine|March 11, 2016
Staphylococcus aureus α toxin potentiates opportunistic bacterial lung infectionsTaylor S Cohen, Jamese J Hilliard, Omari Jones-Nelson, et al.
The Journal of Experimental Medicine|June 27, 2012
Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screeningAntonio DiGiandomenico, Paul Warrener, Melissa Hamilton, et al.
Cell|September 21, 2023
Mpox infection protects against re-challenge in rhesus macaquesMalika Aid, Michaela Sciacca, Katherine McMahan, et al.
The New England Journal of Medicine|January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaHussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
European Urology Oncology|February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell CarcinomaBradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Pageof 4